Downregulation of MALAT1 in triple-negative breast cancer cells

被引:2
|
作者
Klopotowska, Dagmara [1 ]
Matuszyk, Janusz [1 ]
机构
[1] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Rudolfa Weigla 12, PL-53114 Wroclaw, Poland
关键词
Breast cancer cell lines; Non-coding RNA; lncRNA; Real -time PCR; Reference gene; LONG NONCODING RNA; MESENCHYMAL TRANSITION; LNCRNA MALAT1; EXPRESSION; PROGRESSION; METASTASIS; PATHWAY;
D O I
10.1016/j.bbrep.2023.101592
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: MALAT1 is one of the most abundant nuclear long non-coding RNAs, which has been found to be elevated in various types of cancers. However, conflicting reports on MALAT1 in breast cancer cell lines challenge understanding of MALAT1's involvement in breast cancer progression. Aim: Measurement of normalized relative quantity (NRQ) of MALAT1 transcripts in cell lines representing triplenegative breast cancer (TNBC) and luminal breast cancer. Materials and methods: The studies were performed using cell lines representing luminal breast cancer (T47D, MCF-7), TNBC (MDA-MB-468, CAL-51, MDA-MB-231), and MCF-10A cell line of normal breast epithelial cells. Total RNA was isolated from six independent cell cultures of each line, treated with DNase I, and used to synthesize complementary DNA, which was used in quantitative real-time PCR (qPCR) assays. Four MALAT1 fragments and reference genes CCSER2, ANKRD17, PUM1, GAPDH were amplified. Results: Geometric means of the NRQ of MALAT1 in breast cancer cell lines had the shortest 95% confidence intervals when CCSER2 was used for normalization. MALAT1 major transcript levels thus estimated in TNBC cell lines were found to be statistically significantly reduced compared to levels in both MCF-10A cells and luminal breast cancer cell lines, while MALAT1 minority splice variants were found to be increased in almost all breast cancer cell lines. Conclusion: CCSER2-normalized qPCR results indicate MALAT1 downregulation in cell lines representing the more aggressive breast cancer subtype compared to both the normal breast epithelial cell line and the estrogen receptor-positive breast cancer cell lines.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [32] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [33] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [34] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [35] Morphotypes of the triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Korinkova, G.
    Trojanec, R.
    VIRCHOWS ARCHIV, 2017, 471 : S296 - S296
  • [36] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [37] Chemoimmunotherapy for Triple-Negative Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (24): : 2521 - 2521
  • [38] Pembrolizumab for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2020, 21 (04): : E183 - E183
  • [39] Targeting triple-negative breast cancer
    Peter Kirkpatrick
    Nature Reviews Drug Discovery, 2009, 8 : 21 - 21
  • [40] Targeting triple-negative breast cancer
    Kirkpatrick, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) : 21 - 21